Predictors of left ventricular reverse remodeling and subsequent outcome in nonischemic dilated cardiomyopathy

Circulation Journal

Volumn 77, Issue 2, 2013, Pages 462-469

  Choi, Jin Oh ^a   Kim, Eun Young ^a   Lee, Ga Yeon ^a   Lee, Sang Chol ^a   Park, Seung Woo ^a   Kim, Duk Kyung ^a   Oh, Jae K ^b   Jeon, Eun Seok ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Mayo Clinic College of Medicine   (United States)

Author keywords

Dilated cardiomyopathy; Natriuretic peptides; Reverse remodeling

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ADULT; ARTICLE; CONGESTIVE CARDIOMYOPATHY; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART DEATH; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART TRANSPLANTATION; HEART VENTRICLE REMODELING; HUMAN; MAJOR CLINICAL STUDY; MALE; QRS COMPLEX; RETROSPECTIVE STUDY; SURVIVAL; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

ADULT; AGED; CARDIOMYOPATHY, DILATED; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; INCIDENCE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECURRENCE; RISK FACTORS; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84873872212     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-12-0507     Document Type: Article

References (17)

1. Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O'Connell J, et al. Report of the 1995 World Health Organization/ International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 1996; 93: 841-842.
2. Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, et al. Contemporary definitions and classification of the cardiomyopathies: An American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 2006; 113: 1807-1816.
3. Matsumura Y, Takata J, Kitaoka H, Kubo T, Baba Y, Hoshikawa E, et al. Long-term prognosis of dilated cardiomyopathy revisited: An improvement in survival over the past 20 years. Circ J 2006; 70: 376-383.
4. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000; 355: 1126-1130.
5. Nishiyama K, Tsutamoto T, Kawahara C, Yamaji M, Sakai H, Yamamoto T, et al. Relationship between biological variation in Btype natriuretic peptide and plasma renin concentration in stable outpatients with dilated cardiomyopathy. Circ J 2011; 75: 1897-1904.
6. Francis GS, Tang WH. Beta-blockers and reverse remodeling: What are the implications? Am Heart J 2003; 145: 200-202.
7. Merlo M, Pyxaras SA, Pinamonti B, Barbati G, Di Lenarda A, Sinagra G. Prevalence and prognostic significance of left ventricular reverse remodeling in dilated cardiomyopathy receiving tailored medical treatment. J Am Coll Cardiol 2011; 57: 1468-1476.
8. Hoshikawa E, Matsumura Y, Kubo T, Okawa M, Yamasaki N, Kitaoka H, et al. Effect of left ventricular reverse remodeling on long-term prognosis after therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and beta blockers in patients with idiopathic dilated cardiomyopathy. Am J Cardiol 2011; 107: 1065-1070.
9. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling: Concepts and clinical implications: A consensus paper from an international forum on cardiac remodeling: Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 2000; 35: 569-582.
10. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines: Developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119: e391-e479.
11. Picard MH, Adams D, Bierig SM, Dent JM, Douglas PS, Gillam LD, et al. American Society of Echocardiography recommendations for quality echocardiography laboratory operations. J Am Soc Echocardiogr 2011; 24: 1-10.
12. Appleton CP, Hatle LK, Popp RL. Relation of transmitral flow velocity patterns to left ventricular diastolic function: New insights from a combined hemodynamic and Doppler echocardiographic study. J Am Coll Cardiol 1988; 12: 426-440.
13. Barbati G, Merlo M, Marocco P, Gregori D, Sabbadini G, Lattuada L, et al. Relative survival in dilated cardiomyopathy: A stratification study of long-term outcome to evaluate life insurance cover. J Insur Med 2009; 41: 117-126.
14. Metra M, Nodari S, Parrinello G, Giubbini R, Manca C, Dei Cas L. Marked improvement in left ventricular ejection fraction during longterm beta-blockade in patients with chronic heart failure: Clinical correlates and prognostic significance. Am Heart J 2003; 145: 292-299.
15. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure: U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334: 1349-1355.
16. Binkley PF, Lesinski A, Ferguson JP, Hatton PS, Yamokoski L, Hardikar S, et al. Recovery of normal ventricular function in patients with dilated cardiomyopathy: Predictors of an increasingly prevalent clinical event. Am Heart J 2008; 155: 69-74.
17. Frimm CdC, de Moraes AV, Medeiros CC, Esteves Filho A, Marino JC. Normalization of left ventricular dysfunction in systemic hypertension. Clin Cardiol 2000; 23: 443-448.